Pharmaceutical products

Tender description

In response to the Covid-19 vaccine manufacture programme, CPI need to secure supply of linearised plasmid to help develop a self-amplifying RNA Vaccine. This tender is split into 3 lots: 1) to generate and validate a MCB for plasmid production, starting with a provided plasmid template in an appropriate strain of E. coli; 2) from the MCB, supply 10g of purified linearised plasmid manufactured according to GMP. (to simplify the tendering process, CPI will free issue the restriction enzyme for linearization to the successful bidder); 3) provision of the combined services of lot 1 and 2. In response to the Covid-19 Vaccine manufacture programme, CPI need to secure supply of linearised plasmid to help develop a self-amplifying RNA vaccine. CPI requires a supplier to generate and validate a MCB for plasmid production, starting with a provided plasmid template in an appropriate strain of E. coli. In response to the Covid-19 Vaccine manufacture programme, CPI need to secure supply of linearised plasmid to help develop a self-amplifying RNA Vaccine. CPI requires a supplier to supply 10 g of purified linearised plasmid manufactured according to GMP. In response to the Covid-19 Vaccine manufacture programme, CPI need to secure supply of linearised plasmid to help develop a self-amplifying RNA Vaccine. CPI requires a supplier to generate and validate a MCB for plasmid production, starting with a provided plasmid template in an appropriate strain of E. coli. From the MCB, they are expecited supply 10 g of purified linearised plasmid manufactured according to GMP. (To simplify the tendering process, CPI will free issue the restriction enzyme for linearization to the successful bidder).